Charles Schwab Investment Management Inc. Sells 124,875 Shares of QIAGEN N.V. $QGEN

Key Points

• Charles Schwab Investment Management Inc. significantly reduced its stake in Qiagen N.V. by 67.5% during the first quarter, leaving it with 60,091 shares valued at approximately $2.41 million.
• Qiagen reported a 7.7% year-over-year revenue growth in its latest quarter, generating $533.54 million and meeting the consensus EPS estimate of $0.60.
• Barclays and Bank of America have recently issued favorable ratings on Qiagen, with target prices of $55.00 and $53.00 respectively, contributing to a consensus target price of $49.69.

Charles Schwab Investment Management Inc. lowered its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 67.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,091 shares of the company's stock after selling 124,875 shares during the period. Charles Schwab Investment Management Inc.'s holdings in QIAGEN were worth $2,413,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd acquired a new stake in shares of QIAGEN in the 1st quarter valued at $94,000. Tower Research Capital LLC TRC boosted its stake in shares of QIAGEN by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares in the last quarter. Federated Hermes Inc. acquired a new stake in shares of QIAGEN in the 1st quarter valued at $150,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of QIAGEN in the 4th quarter valued at $202,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on QGEN. Barclays began coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Wall Street Zen downgraded shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Cowen restated a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Bank of America boosted their target price on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Finally, UBS Group lifted their price target on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $49.69.

QIAGEN Trading Up 0.9%

NYSE:QGEN traded up $0.39 on Monday, hitting $46.53. 1,965,193 shares of the stock were exchanged, compared to its average volume of 1,519,147. The stock has a market capitalization of $10.34 billion, a price-to-earnings ratio of 19.82, a P/E/G ratio of 2.57 and a beta of 0.64. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The company's 50-day moving average price is $48.70 and its 200 day moving average price is $44.21.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities research analysts forecast that QIAGEN N.V. will post 2.26 earnings per share for the current year.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.